An enhanced model that integrates non-AJCC clinical features provides clinicians with a more accurate tool for identifying high-risk patients with MCC.
Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback